Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety

Leukemia

Volumn 27, Issue 8, 2013, Pages 1707-1714

  Badros, A Z ^a   Vij, R ^b   Martin, T ^c   Zonder, J A ^d   Kunkel, L ^e   Wang, Z ^f   Lee, S ^f   Wong, A F ^f   Niesvizky, R ^g  

^a UNIVERSITY OF MARYLAND   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Independent Consultant   (United States)

^f ONYX PHARMACEUTICALS   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

carfilzomib; dialysis; myeloma; proteasome inhibitor; relapsed; renal impairment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CORTICOSTEROID; CREATININE; HEMOGLOBIN; LENALIDOMIDE; PROTEASOME; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84881480747     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.29     Document Type: Article

References (29)

1. Bladé J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893. (Pubitemid 28440861)
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
3. Sengul S, Li M, Batuman V. Myeloma kidney: toward its prevention-with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009; 22: 17-28.
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207-212. (Pubitemid 24347964)
5. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33. (Pubitemid 36033957)
6. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27(2): 423-429.
7. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzo-mib: a link to clinical adverse events. Clin Cancer Res 2011; 17: 2734-2743.
8. Lee S, Arastu-Kapur S, Kellerman L, Woo T, Wong A, Papadopoulos K et al. Potent inhibition of select proteasome subunits by carfilzomib in multiple myeloma and solid tumor patients is associated with patient response [abstract 0840]. Haematologica 2012; 97: 344.
9. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
10. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-5670.
11. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593-1599.
12. Martin T, Vij R, Badros A, Patel P, McCulloch L, Jagannath S. Carfilzomib is associated with a low rate of typically mild to moderate, non-dose limiting treatment-emergent peripheral neuropathy [abstract 0857]. Haematologica 2012; 97: 352.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Revision 1, March 2010.
14. Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012; 18: 4830-4840.
15. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085-7091.
16. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0. 2006 31 March, 2003 Available from http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf.
17. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473. (Pubitemid 44264086)
18. Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123. (Pubitemid 28435189)
19. Siegel D, Wang M, Martin T, Infante J, Kaufman JL, Ranjangam K et al. A phase 2 study of prolonged carfilzomib therapy in patients with multiple myeloma previously enrolled in carfilzomib phase 1 and 2 clinical trials [abstract]. Blood 2012; 120: Abstract 2962.
20. Lee P, Wong AF, Burris HA, Papadopoulos K, Sausville EA, Rosen PJ et al. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies [abstract]. J Clin Oncol 2010; 28: 8147.
21. Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H et al. Pharmacokinetics, phar-macodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 2011; 39: 1873-1882.
22. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012; 158: 739-748.
23. Nooka A. Hematologic safety profile of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma from four phase 2 studies [abstract 1515]. Haematologica 2012; 97: 601.
24. Singhal S, Siegel D, Martin T, Vij R, Wang M, Jakubowiak A et al. Integrated safety data from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis [abstract]. Blood 2011; 118: Abstract 1876.
25. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
26. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604-2606. (Pubitemid 46425908)
27. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146: 619-626.
28. Niesvizky R, Bensinger W, Martin T, Alsina M, Siegel D, Gabrail N et al. An update on the phase 1b/2 dose-escalation study of carfilzomib with lenalidomide and low-dose dexamethasone (CRd) in patients with relapsed or refractory multiple myeloma (abstract 0295). Haematologica 2011; 96: 122.
29. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012; 120: 1801-1809.